M&T Bank
TRIB

M&T Bank’s Trinity Biotech TRIB Stock Holding History

M&T Bank’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-2,600
Closed -$172K – 1761
2016
Q3 		$172K Hold
2,600
– – ﹤0.01% 1517
2016
Q2 		$147K Hold
2,600
– – ﹤0.01% 1490
2016
Q1 		$152K Hold
2,600
– – ﹤0.01% 1522
2015
Q4 		$153K Hold
2,600
– – ﹤0.01% 1545
2015
Q3 		$149K Buy
+2,600
New +$209K ﹤0.01% 1586

Other funds holding TRIB

PIM
Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
LAM
Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return
SCM
Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

M&T Bank's TRIB Position: Q4 2016 in Review

M&T Bank sold out of Trinity Biotech (TRIB) in Q4 2016, closing a stake of 2,600 shares — an estimated $172K sold.

M&T Bank first reported a position in TRIB in Q3 2015 and held it in 5 quarters. The position peaked at $172K in Q3 2016. 71 funds tracked by Wall St. Rank hold TRIB as of Q4 2016.

  • M&T Bank reported no remaining Trinity Biotech position as of Q4 2016 after selling out during the quarter.
  • M&T Bank sold 2,600 Trinity Biotech shares in Q4 2016, an estimated $172K.
  • M&T Bank first reported a position in Trinity Biotech in Q3 2015 and held it in 5 quarters.
  • M&T Bank's Trinity Biotech position peaked at $172K in Q3 2016.
  • 71 funds tracked by Wall St. Rank held Trinity Biotech as of Q4 2016.

Based on M&T Bank's 13F filing for Q4 2016, filed 14 Feb 2017.